

# Resource Summary Report

Generated by RRID on Aug 2, 2026

## PD1 antibody [NAT]

RRID:AB\_881954

Type: Antibody

---

### Proper Citation

Abcam Cat# ab52587, RRID:AB\_881954

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_881954](http://antibodyregistry.org/AB_881954)

**Proper Citation:** Abcam Cat# ab52587, RRID:AB\_881954

**Target Antigen:** TY cells (human T/NK cell Leukemia

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Used By NYUIHC-835

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:TRUE, Functional in animal:FALSE, NonFunctional in animal:FALSE

**Antibody Name:** PD1 antibody [NAT]

**Description:** This monoclonal targets TY cells (human T/NK cell Leukemia

**Target Organism:** human

**Clone ID:** [NAT]

**Antibody ID:** AB\_881954

**Vendor:** Abcam

**Catalog Number:** ab52587

**Record Creation Time:** 20250820T013254+0000

**Record Last Update:** 20250820T111328+0000

---

### Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:TRUE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for PD1 antibody [NAT].

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 22 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Liu L, et al. (2025) Isoformic PD-1 impedes B cell activation and function in HIV-1 infection. Cell reports, 44(10), 116341.

Huyghe N, et al. (2025) Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan. Cell reports. Medicine, 6(7), 102201.

Martins C, et al. (2024) Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling. Science advances, 10(3), eadi2012.

Tran K, et al. (2024) T cell factor 1 (TCF-1) defines T cell differentiation in colorectal cancer. iScience, 27(9), 110754.

Wang B, et al. (2024) Glycolysis Induced by METTL14 Is Essential for Macrophage Phagocytosis and Phenotype in Cervical Cancer. Journal of immunology (Baltimore, Md. : 1950), 212(4), 723.

Zhang J, et al. (2024) Osr2 functions as a biomechanical checkpoint to aggravate CD8+ T cell exhaustion in tumor. Cell, 187(13), 3409.

Li Y, et al. (2024) Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. Cell reports. Medicine, 5(2), 101397.

Bao X, et al. (2024) A multiomics analysis-assisted deep learning model identifies a macrophage-oriented module as a potential therapeutic target in colorectal cancer. Cell reports. Medicine, 5(2), 101399.

Ma S, et al. (2024) Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity. Cancer cell.

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. *Cancer cell*, 41(5), 837.

Johnson BE, et al. (2022) An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. *Cell reports. Medicine*, 3(2), 100525.

Wen J, et al. (2022) Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma. *EBioMedicine*, 86, 104371.

Meylan M, et al. (2022) Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. *Immunity*, 55(3), 527.

Ducoin K, et al. (2022) Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy. *Cancers*, 14(17).

Wheeler DA, et al. (2021) Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. *Cancer cell*, 39(1), 38.

Hornburg M, et al. (2021) Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. *Cancer cell*, 39(7), 928.

Au L, et al. (2021) Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. *Cancer cell*, 39(11), 1497.

Maynard A, et al. (2020) Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. *Cell*, 182(5), 1232.

Salvador-Barbero B, et al. (2020) CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. *Cancer cell*, 37(3), 340.

Toulmonde M, et al. (2020) High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. *EBioMedicine*, 62, 103131.